## Pierre I Karakiewicz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7829305/publications.pdf

Version: 2024-02-01

344 papers 8,001 citations

41 h-index 75 g-index

345 all docs 345 docs citations

times ranked

345

6382 citing authors

#	Article	IF	CITATIONS
1	Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. Journal of Racial and Ethnic Health Disparities, 2023, 10, 708-717.	1.8	3
2	Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. European Urology Focus, 2022, 8, 182-190.	1.6	15
3	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aNOMO Renal Cell Carcinoma Patients. European Urology Focus, 2022, 8, 191-199.	1.6	8
4	Tumor Size Predicts Muscle-invasive and Non–organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. European Urology Focus, 2022, 8, 498-505.	1.6	17
5	Reducing the Risk of Postoperative Complications After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients: Results of an Audit and Feedback Intervention Following the Implementation of Prospective Data Collection. European Urology Focus, 2022, 8, 431-437.	1.6	5
6	Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. European Urology Focus, 2022, 8, 399-408.	1.6	29
7	Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. European Urology Focus, 2022, 8, 710-717.	1.6	12
8	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. European Urology Focus, 2022, 8, 761-768.	1.6	10
9	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 85-95.	2.0	6
10	Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer and Prostatic Diseases, 2022, 25, 139-148.	2.0	28
11	Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy. European Urology Focus, 2022, 8, 1133-1140.	1.6	11
12	The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 57.e15-57.e23.	0.8	7
13	PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 7.e1-7.e8.	0.8	6
14	Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 59.e7-59.e12.	0.8	5
15	The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. World Journal of Urology, 2022, 40, 103-110.	1.2	9
16	External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. International Journal of Urology, 2022, 29, 17-24.	0.5	7
17	Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.  European Urology Oncology, 2022, 5, 1-17.	2.6	50
18	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. Cancer Causes and Control, 2022, 33, 25-35.	0.8	4

#	Article	IF	CITATIONS
19	Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Journal of Urology, 2022, 207, 16-24.	0.2	31
20	Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Journal of Urology, 2022, 207, 375-384.	0.2	18
21	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Molecular Carcinogenesis, 2022, 61, 5-18.	1.3	6
22	Improving the stratification of intermediate risk prostate cancer. Minerva Urology and Nephrology, 2022, 74, .	1.3	10
23	Cancerâ€specific survival after radical prostatectomy versus external beam radiotherapy in highâ€risk and very highâ€risk African American prostate cancer patients. Prostate, 2022, 82, 120-131.	1.2	2
24	Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 165.e9-165.e15.	0.8	8
25	Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. Prostate, 2022, 82, 78-85.	1.2	3
26	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. World Journal of Urology, 2022, 40, 747-754.	1.2	4
27	Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder. Clinical Genitourinary Cancer, 2022, 20, 195.e1-195.e8.	0.9	3
28	Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. International Journal of Urology, 2022, 29, 96-96.	0.5	3
29	Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 169, 103534.	2.0	5
30	Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate. International Urology and Nephrology, 2022, 54, 89-95.	0.6	2
31	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. Clinical Genitourinary Cancer, 2022, 20, 227-236.	0.9	3
32	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Minerva Urology and Nephrology, 2022, 74, .	1.3	8
33	The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy. European Journal of Surgical Oncology, 2022, 48, 1840-1847.	0.5	3
34	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. European Urology Oncology, 2022, 5, 120-124.	2.6	6
35	Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. Prostate International, 2022, 10, 21-27.	1.2	3
36	Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients. World Journal of Urology, 2022, 40, 1481-1488.	1.2	8

#	Article	IF	Citations
37	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. Scandinavian Journal of Urology, 2022, 56, 85-93.	0.6	3
38	Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 271.e19-271.e27.	0.8	25
39	Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. Urologia Internationalis, 2022, 106, 1150-1157.	0.6	5
40	Survival after radical prostatectomy versusÂradiation therapy in clinical nodeâ€positive prostate cancer. Prostate, 2022, 82, 740-750.	1.2	7
41	Oncologic impact of concomitant prostate cancer characteristics at the time of radical cystoprostatectomy for bladder cancer: a population-based analysis. Aging Male, 2022, 25, 54-61.	0.9	1
42	Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. Prostate, 2022, 82, 676-686.	1.2	4
43	Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. Cancers, 2022, 14, 1222.	1.7	7
44	Nonâ€organ confined stage and upgrading rates in exclusive PSA highâ€risk prostate cancer patients. Prostate, 2022, 82, 687-694.	1.2	3
45	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	1.2	O
46	Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. Cancer Causes and Control, 2022, 33, 769-777.	0.8	1
47	Urethral Sphincter Length but Not Prostatic Apex Shape in Preoperative MRI Is Associated with Mid-Term Continence Rates after Radical Prostatectomy. Diagnostics, 2022, 12, 701.	1.3	3
48	Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Reply Journal of Urology, 2022, , 101097JU000000000002681.	0.2	0
49	Grade and stage misclassification in intermediate unfavorableâ€risk prostate cancer radiotherapy candidates. Prostate, 2022, , .	1.2	4
50	Response to the letter to the editor: "Don't throw the baby out with the bath water―by Horsley et al Prostate, 2022, 82, 399-400.	1.2	2
51	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. Journal of Robotic Surgery, 2022, 16, 1233-1247.	1.0	6
52	High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality. Cancers, 2022, 14, 1623.	1.7	5
53	Contemporary seminal vesicle invasion rates in NCCN highâ€risk prostate cancer patients. Prostate, 2022, 82, 1051-1059.	1.2	6
54	Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 380.e19-380.e27.	0.8	7

#	Article	lF	CITATIONS
55	Full functional-length urethral sphincter- and neurovascular bundle preservation improves long-term continence rates after robotic-assisted radical prostatectomy. Journal of Robotic Surgery, 2022, , 1.	1.0	2
56	Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity. International Urology and Nephrology, 2022, 54, 1521-1527.	0.6	10
57	Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level. Prostate, 2022, 82, 1210-1218.	1.2	2
58	Outcomes of roboticâ€assisted versus open radical cystectomy in a largeâ€scale, contemporary cohort of bladder cancer patients. Journal of Surgical Oncology, 2022, 126, 830-837.	0.8	7
59	Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages—A SEER-based Study. European Urology Focus, 2021, 7, 1332-1338.	1.6	8
60	Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. European Urology Oncology, 2021, 4, 792-801.	2.6	40
61	The impact of intraoperative bleeding on the risk of chronic kidney disease after nephron-sparing surgery. World Journal of Urology, 2021, 39, 2553-2558.	1.2	12
62	Differences between rural and urban prostate cancer patients. World Journal of Urology, 2021, 39, 2507-2514.	1.2	12
63	Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database–based Study. European Urology Focus, 2021, 7, 818-826.	1.6	7
64	Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. World Journal of Urology, 2021, 39, 461-472.	1.2	15
65	Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. European Journal of Surgical Oncology, 2021, 47, 463-469.	0.5	7
66	Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. World Journal of Urology, 2021, 39, 813-822.	1.2	6
67	Holmium laser enucleation of the prostate: efficacy, safety and preoperative management in patients presenting with anticoagulation therapy. World Journal of Urology, 2021, 39, 1219-1226.	1.2	15
68	Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. European Urology, 2021, 79, 44-53.	0.9	61
69	PSA, stage, grade and prostate cancer specific mortality in Asian American patients relative to Caucasians according to the United States Census Bureau race definitions. World Journal of Urology, 2021, 39, 787-796.	1.2	10
70	Primary Ta high grade bladder tumors: Determination of the risk of progression. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 132.e7-132.e11.	0.8	9
71	Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 75.e17-75.e25.	0.8	7
72	Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. Clinical Genitourinary Cancer, 2021, 19, 60-68.e1.	0.9	27

#	Article	IF	CITATIONS
73	The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 236.e1-236.e7.	0.8	10
74	External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 131.e1-131.e7.	0.8	2
75	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e5-235.e14.	0.8	8
76	Improving the Stratification of Patients With Intermediate-risk Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, e120-e128.	0.9	8
77	Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and metaâ€analyses. BJU International, 2021, 128, 3-11.	1.3	25
78	Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1–4Âcm renal cell carcinomas. Cancer Causes and Control, 2021, 32, 119-126.	0.8	1
79	Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. European Journal of Surgical Oncology, 2021, 47, 1187-1190.	0.5	11
80	Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. Surgical Oncology, 2021, 36, 131-137.	0.8	4
81	The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 369.e9-369.e17.	0.8	4
82	Bladder cancer stage and mortality: urban vs. rural residency. Cancer Causes and Control, 2021, 32, 139-145.	0.8	10
83	Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review.  Arab Journal of Urology Arab Association of Urology, 2021, 19, 59-66.	0.7	12
84	Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 234.e1-234.e7.	0.8	3
85	Re: Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. Eur Urol 2020;78:360–368. European Urology, 2021, 79, e33-e34.	0.9	0
86	External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. Prostate Cancer and Prostatic Diseases, 2021, 24, 253-260.	2.0	6
87	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. OncoTargets and Therapy, 2021, Volume 14, 315-324.	1.0	5
88	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. World Journal of Urology, 2021, 39, 3345-3352.	1.2	18
89	Multiparametric MRI may Help to Identify Patients With Prostate Cancer in a Contemporary Cohort of Patients With Clinical Bladder Outlet Obstruction Scheduled for Holmium Laser Enucleation of the Prostate (HoLEP). Frontiers in Surgery, 2021, 8, 633196.	0.6	8
90	Sex- and age-related differences in the distribution of bladder cancer metastases. Japanese Journal of Clinical Oncology, 2021, 51, 976-983.	0.6	11

#	Article	IF	CITATIONS
91	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. Turkish Journal of Urology, 2021, 47, S33-S44.	1.3	1
92	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Translational Andrology and Urology, 2021, 10, 609-619.	0.6	5
93	Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy. International Urology and Nephrology, 2021, 53, 1297-1303.	0.6	12
94	Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. Journal of Clinical Pathology, 2021, , jclinpath-2021-207400.	1.0	5
95	The effect of lymph node dissection on cancerâ€specific survival in salvage radical prostatectomy patients. Prostate, 2021, 81, 339-346.	1.2	13
96	Incidence rates and contemporary trends in primary urethral cancer. Cancer Causes and Control, 2021, 32, 627-634.	0.8	15
97	Higher Cancer Mortality in Rural Upper Urinary Tract Urothelial Carcinoma Patients. Urologia Internationalis, 2021, 105, 624-630.	0.6	6
98	Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. Clinical Genitourinary Cancer, 2021, 19, 135-143.	0.9	7
99	Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 239.e1-239.e7.	0.8	5
100	Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. Clinical Genitourinary Cancer, 2021, 19, 117-124.	0.9	22
101	Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies. Frontiers in Oncology, 2021, 11, 659135.	1.3	16
102	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non–clear Cell Renal Cell Carcinoma Patients. European Urology Focus, 2021, 7, 598-607.	1.6	10
103	Nonâ€cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. Prostate, 2021, 81, 728-735.	1.2	11
104	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 785.e11-785.e17.	0.8	6
105	Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. World Journal of Urology, 2021, 39, 4085-4099.	1.2	9
106	Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. World Journal of Urology, 2021, 39, 3781-3787.	1.2	9
107	Reply to the letter to the editor: RE: Wenzel M, et al. The effect of lymph node dissection on cancerâ€specific survival in salvage radical prostatectomy patients. The Prostate. 2021;1–8. Prostate, 2021, 81, 795-795.	1.2	0
108	The role of nephrectomy in metastatic renal cell carcinoma in the immunoâ€oncology era. BJU International, 2021, 128, 438-439.	1.3	6

#	Article	IF	CITATIONS
109	Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American populationâ€based study. International Journal of Urology, 2021, 28, 834-839.	0.5	5
110	Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. Diagnostics, 2021, 11, 882.	1.3	13
111	Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns+. Prostate, 2021, 81, 778-784.	1.2	2
112	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. International Journal of Urology, 2021, 28, 862-869.	0.5	22
113	Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy. World Journal of Urology, 2021, 39, 4127-4133.	1.2	3
114	Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. International Journal of Clinical Oncology, 2021, 26, 1707-1713.	1.0	5
115	Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 830.e17-830.e26.	0.8	17
116	Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. Surgical Oncology, 2021, 37, 101519.	0.8	2
117	Immunohistochemistry for Prostate Biopsy—Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making. Current Oncology, 2021, 28, 2123-2133.	0.9	10
118	Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 789.e9-789.e17.	0.8	5
119	Twentyâ€year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort. Prostate, 2021, 81, 849-856.	1.2	14
120	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. Journal of Urology, 2021, 206, 1122-1131.	0.2	5
121	Increasing rates of NCCN high and very highâ€risk prostate cancer versus number of prostate biopsy cores. Prostate, 2021, 81, 874-881.	1.2	15
122	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. International Journal of Clinical Oncology, 2021, 26, 1729-1735.	1.0	3
123	Longâ€term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using lifeâ€table data. Prostate, 2021, 81, 785-793.	1.2	6
124	Reply by Authors. Journal of Urology, 2021, 206, 79-79.	0.2	0
125	Assessment of the optimal number of positive biopsy cores to discriminate between cancerâ€specific mortality in highâ€risk versus very highâ€risk prostate cancer patients. Prostate, 2021, 81, 1055-1063.	1.2	2
126	Diagnostic Performance of Magnetic Resonance Imaging for Preoperative Local Staging of Penile Cancer: A Systematic Review and Meta-Analysis. Applied Sciences (Switzerland), 2021, 11, 7090.	1.3	4

#	Article	IF	CITATIONS
127	The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 788.e7-788.e13.	0.8	6
128	Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. Journal of Urology, 2021, 206, 69-79.	0.2	12
129	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 764-773.	0.8	14
130	Radical Cystectomy vs. Multimodality Treatment in T2NOMO Bladder Cancer: A Population-based, Age-matched Analysis. Clinical Genitourinary Cancer, 2021, 19, e264-e271.	0.9	9
131	The effect of primary urological cancers on survival in men with secondary prostate cancer. Prostate, 2021, 81, 1149-1158.	1.2	5
132	Catheterization Does Not Improve Course of Disease in Female Patients with Acute Cystitis or Pyelonephritis: Retrospective Analysis of >300 In-Hospital Treated Patients. Urologia Internationalis, 2021, 105, 1-9.	0.6	1
133	Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. Clinical Genitourinary Cancer, 2021, 19, e255-e263.	0.9	8
134	Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. European Journal of Cancer, 2021, 155, 245-255.	1.3	2
135	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. Surgical Oncology, 2021, 38, 101588.	0.8	8
136	Improvement in overall and cancerâ€specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. Prostate, 2021, 81, 1374-1381.	1.2	8
137	Increased risk of postoperative inâ€hospital complications after radical prostatectomy in patients with prior organ transplant. Prostate, 2021, 81, 1294-1302.	1.2	0
138	Stage and cancerâ€specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American populationâ€based study. International Journal of Urology, 2021, 28, 1247-1252.	0.5	3
139	Radical cystectomy vs radiotherapy in urothelial bladder cancer in elderly and very elderly patients. Clinical Genitourinary Cancer, 2021, , .	0.9	2
140	Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort. European Urology, 2021, 80, 400-404.	0.9	4
141	The Impact of Preoperative Double-J Stent on Perioperative Complications, Recurrence, and Quality of Life in Adult Patients Undergoing Pyeloplasty. Urologia Internationalis, 2021, , 1-8.	0.6	0
142	Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries. Cancer Epidemiology, 2021, 74, 101994.	0.8	8
143	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. International Journal of Clinical Oncology, 2021, 26, 962-970.	1.0	4
144	Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 74.e1-74.e7.	0.8	4

#	Article	IF	CITATIONS
145	Comparison of Complication Rates with Antibiotic Prophylaxis with Cefpodoxime Versus Fluoroquinolones After Transrectal Prostate Biopsy. European Urology Focus, 2021, 7, 980-986.	1.6	3
146	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. World Journal of Urology, 2021, , 1.	1.2	3
147	The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. Frontiers in Oncology, 2021, 11, 754996.	1.3	0
148	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 778858.	1.3	7
149	Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. International Urology and Nephrology, 2021, 54, 81.	0.6	1
150	Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy. Current Oncology, 2021, 28, 4738-4747.	0.9	10
151	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. Minerva Urology and Nephrology, 2021, 73, 610-615.	1.3	6
152	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. Minerva Urology and Nephrology, 2021, , .	1.3	4
153	Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 534-540.	2.3	7
154	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Minerva Urology and Nephrology, 2021, , .	1.3	8
155	Anatomical Fundamentals and Current Surgical Knowledge of Prostate Anatomy Related to Functional and Oncological Outcomes for Robotic-Assisted Radical Prostatectomy. Frontiers in Surgery, 2021, 8, 825183.	0.6	14
156	Influence of Biopsy Gleason Score on the Risk of Lymph Node Invasion in Patients With Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy. Frontiers in Surgery, 2021, 8, 759070.	0.6	1
157	External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. International Urology and Nephrology, 2020, 52, 59-66.	0.6	4
158	Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. European Urology Oncology, 2020, 3, 631-639.	2.6	4
159	Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. Clinical Genitourinary Cancer, 2020, 18, 129-137.e3.	0.9	11
160	Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. Journal of Geriatric Oncology, 2020, 11, 718-723.	0.5	21
161	Comparison of intra- and postoperative analgesia and pain perception in robot-assisted vs. open radical prostatectomy. World Journal of Urology, 2020, 38, 1451-1457.	1.2	14
162	Prostate cancer characteristics and cancer-specific mortality of Native American patients. Prostate Cancer and Prostatic Diseases, 2020, 23, 277-285.	2.0	6

#	Article	IF	CITATIONS
163	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. Clinical Genitourinary Cancer, 2020, 18, 35-44.e1.	0.9	2
164	Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 79.e9-79.e14.	0.8	18
165	A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. Clinical Genitourinary Cancer, 2020, 18, 314-321.e1.	0.9	11
166	Re: Jack R. Andrews, Thomas Atwell, Grant Schmit, et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol 2019;76:244–51. European Urology, 2020, 77, e74.	0.9	0
167	Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. Clinical Genitourinary Cancer, 2020, 18, e450-e456.	0.9	5
168	Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. World Journal of Urology, 2020, 38, 2501-2511.	1.2	9
169	Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 2020, 18, e402-e409.	0.9	15
170	Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 76.e1-76.e9.	0.8	22
171	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. Clinical Genitourinary Cancer, 2020, 18, 117-128.e5.	0.9	6
172	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 936.e7-936.e14.	0.8	3
173	The Effect of Adverse Patient Characteristics on Perioperative Outcomes in Open and Robot-Assisted Radical Prostatectomy. Frontiers in Surgery, 2020, 7, 584897.	0.6	6
174	Catheter Management and Risk Stratification of Patients With in Inpatient Treatment Due to Acute Epididymitis. Frontiers in Surgery, 2020, 7, 609661.	0.6	3
175	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 567-574.	0.6	3
176	Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure. Current Opinion in Supportive and Palliative Care, 2020, 14, 276-285.	0.5	6
177	An up-to-date catalogue of urinary markers for the management of prostate cancer. Current Opinion in Urology, 2020, Publish Ahead of Print, 684-688.	0.9	2
178	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e730-e738.	0.9	9
179	An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer. Expert Review of Molecular Diagnostics, 2020, 20, 841-850.	1.5	11
180	Stratification of Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. European Urology Focus, 2020, 7, 566-573.	1.6	14

#	Article	IF	CITATIONS
181	Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma. Urology, 2020, 140, 91-97.	0.5	2
182	Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 506-514.	0.8	4
183	Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. Journal of Endourology, 2020, 34, 600-607.	1.1	6
184	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2020, 23, 573-580.	2.0	22
185	Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. Urologic Oncology: Seminars and Original Investigations. 2020. 38. 602.e11-602.e19.	0.8	11
186	Contemporary conditional cancerâ€specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. Journal of Surgical Oncology, 2020, 121, 1154-1161.	0.8	20
187	The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. Cancer Causes and Control, 2020, 31, 283-290.	0.8	9
188	Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 537-544.	0.8	13
189	Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 184-190.	0.8	13
190	Preoperative frailty predicts adverse shortâ€term postoperative outcomes in patients treated with radical nephroureterectomy. Journal of Surgical Oncology, 2020, 121, 688-696.	0.8	19
191	The impact of very high initial PSA on oncological outcomes after radical prostatectomy for clinically localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 379-385.	0.8	8
192	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. Cancer Causes and Control, 2020, 31, 263-272.	0.8	9
193	Rates of otherâ€cause mortality after radical cystectomy are decreasing over time—A populationâ€based analysis over two decades. Journal of Surgical Oncology, 2020, 121, 1329-1336.	0.8	5
194	Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis. Clinical Genitourinary Cancer, 2020, 18, e517-e522.	0.9	11
195	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e610-e618.	0.9	10
196	Intermediate-risk Prostate Cancer: Stratification and Management. European Urology Oncology, 2020, 3, 270-280.	2.6	51
197	The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC). Urologic Oncology: Seminars and Original Investigations, 2020, 38, 423-432.	0.8	4
198	Comparison Between Urothelial and Non-Urothelial Urethral Cancer. Frontiers in Oncology, 2020, 10, 629692.	1.3	8

#	Article	IF	Citations
199	Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. World Journal of Urology, 2020, 38, 2819-2826.	1.2	10
200	Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy. Journal of Urology, 2020, 203, 299-303.	0.2	18
201	Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities. Journal of Urology, 2020, 204, 671-676.	0.2	17
202	The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer. Journal of Urology, 2020, 204, 962-968.	0.2	11
203	Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1492-1499.	2.3	8
204	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 685.e17-685.e25.	0.8	2
205	Racial differences in the distribution of bladder cancer metastases: a population-based analysis. Central European Journal of Urology, 2020, 73, 407-415.	0.2	3
206	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 880-888.	0.6	5
207	Validation of the Social Security Administration Life Tables (2004–2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. European Urology Focus, 2019, 5, 807-814.	1.6	22
208	A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 395-401.	0.9	9
209	Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors. Clinical Genitourinary Cancer, 2019, 17, e1026-e1035.	0.9	19
210	Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 578.e11-578.e19.	0.8	9
211	How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 893-899.	0.8	14
212	Impact of Obesity on Perioperative Outcomes at Robotic-assisted and Open Radical Prostatectomy: Results From the National Inpatient Sample. Urology, 2019, 133, 135-144.	0.5	18
213	The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 659-671.	0.8	21
214	Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. Clinical Genitourinary Cancer, 2019, 17, e1153-e1162.	0.9	8
215	The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. Journal of Surgical Oncology, 2019, 120, 1266-1275.	0.8	6
216	Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. International Urology and Nephrology, 2019, 51, 2181-2188.	0.6	12

#	Article	IF	Citations
217	Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319–28. European Urology, 2019, 75, e98-e99.	0.9	1
218	Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 774-783.	0.8	5
219	Contemporary clinicopathological characteristics of pTO prostate cancer at radical prostatectomy: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 696-701.	0.8	1
220	Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. Clinical Genitourinary Cancer, 2019, 17, e793-e801.	0.9	5
221	Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 702-710.	0.8	10
222	Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: AÂPopulation-Based Study. Clinical Genitourinary Cancer, 2019, 17, 231-237.e2.	0.9	21
223	Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 430-436.	0.8	50
224	External validation of a nomogram for the prediction of 10-year life expectancy in candidates for radical prostatectomy. World Journal of Urology, 2019, 37, 2649-2655.	1.2	6
225	Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. BJU International, 2019, 124, 738-745.	1.3	32
226	Impact of the estimated blood loss during radical prostatectomy on functional outcomes. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 298.e11-298.e17.	0.8	7
227	Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. World Journal of Urology, 2019, 37, 1557-1570.	1.2	15
228	Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 273-281.	0.8	12
229	Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. Cancer Epidemiology, 2019, 59, 135-142.	0.8	9
230	AUTHOR REPLY. Urology, 2019, 133, 142-143.	0.5	1
231	Prognostic value of modified Glasgow Prognostic Score in non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 179.e19-179.e28.	0.8	25
232	Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. European Urology, 2019, 75, 649-658.	0.9	82
233	Role of serum cholinesterase in patients treated with salvage radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 123-129.	0.8	10
234	Complications and functional outcomes of high-risk patient with cardiovascular disease on antithrombotic medication treated with the 532-nm-laser photo-vaporization Greenlight XPS-180 W for benign prostate hyperplasia. World Journal of Urology, 2019, 37, 1671-1678.	1.2	22

#	Article	IF	Citations
235	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. World Journal of Urology, 2019, 37, 1631-1637.	1.2	5
236	Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e130-e139.	0.9	23
237	Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?. Cancer Epidemiology, 2019, 58, 83-88.	0.8	15
238	Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319–28. European Urology, 2019, 75, e95.	0.9	O
239	The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. World Journal of Urology, 2019, 37, 1127-1135.	1.2	9
240	External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. European Urology, 2019, 75, 319-328.	0.9	57
241	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 2019, 5, 97-103.	1.6	3
242	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. European Urology Focus, 2019, 5, 381-388.	1.6	12
243	The Impact of Lymph Node Metastases Burden at Radical Prostatectomy. European Urology Focus, 2019, 5, 399-406.	1.6	19
244	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. European Urology Focus, 2019, 5, 467-473.	1.6	21
245	Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience. European Urology Focus, 2019, 5, 568-576.	1.6	5
246	Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. European Urology Focus, 2019, 5, 488-496.	1.6	41
247	Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis. Journal of Urology, 2019, 201, 46-55.	0.2	17
248	Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e1-239.e7.	0.8	28
249	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e9-239.e15.	0.8	6
250	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 81.e17-81.e24.	0.8	18
251	Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e619-e627.	0.9	4
252	Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer. European Urology Focus, 2018, 4, 834-841.	1.6	7

#	Article	IF	CITATIONS
253	Does surgical delay for radical prostatectomy affect biochemical recurrence? A retrospective analysis from a Canadian cohort. World Journal of Urology, 2018, 36, 1-6.	1.2	20
254	Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 8.e17-8.e24.	0.8	36
255	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, e141-e149.	0.9	10
256	Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e73-e78.	0.9	13
257	External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: AÂPopulation-based Study. Clinical Genitourinary Cancer, 2018, 16, e59-e65.	0.9	1
258	Impact of age on outcomes of patients with non–muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 89.e1-89.e5.	0.8	6
259	Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. World Journal of Urology, 2018, 36, 231-240.	1.2	32
260	Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 528.e7-528.e13.	0.8	6
261	North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. British Journal of Cancer, 2018, 119, 1552-1556.	2.9	10
262	Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. International Journal of Urology, 2018, 25, 929-936.	0.5	3
263	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. Cancer Epidemiology, 2018, 54, 112-118.	0.8	13
264	Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. European Urology Oncology, 2018, 1, 160-168.	2.6	15
265	Prognostic Value of Serum Cholinesterase in Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e1123-e1132.	0.9	19
266	Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 365.e1-365.e7.	0.8	9
267	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 251-259.	1.2	33
268	Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World Journal of Urology, 2017, 35, 337-353.	1.2	74
269	External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 33.e21-33.e26.	0.8	10
270	Multicenter international experience of 532Ânm-laser photo-vaporization with Greenlight XPS in men with large prostates (prostate volume > 100Âcc). World Journal of Urology, 2017, 35, 1603-1609.	1.2	41

#	Article	IF	CITATIONS
271	Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 243-249.	0.8	11
272	Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World Journal of Urology, 2017, 35, 1541-1547.	1.2	41
273	Prediction of Competing Mortality for Decision-making Between Surgery or Observation in Elderly Patients With T1 Kidney Cancer. Urology, 2017, 102, 130-137.	0.5	11
274	Preoperative anemia is associated with disease recurrence and progression in patients with non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 113.e9-113.e14.	0.8	7
275	Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. Urology, 2017, 106, 119-124.	0.5	8
276	External Beam Radiotherapy Affects Serum Testosterone in Patients with Localized Prostate Cancer. Journal of Sexual Medicine, 2017, 14, 876-882.	0.3	16
277	Prognostic role of N-cadherin expression in patients with non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 264-271.	0.8	30
278	Local Therapy Improves Survival in Metastatic Prostate Cancer. European Urology, 2017, 72, 118-124.	0.9	100
279	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 356-362.	0.8	4
280	Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. European Journal of Surgical Oncology, 2017, 43, 2193-2199.	0.5	9
281	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e1039-e1045.	0.9	14
282	Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. Canadian Urological Association Journal, 2016, 10, 82.	0.3	21
283	Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. Translational Andrology and Urology, 2016, 5, 720-734.	0.6	15
284	Reply from Authors re: Matthew C. Hayes, David J. Breen. Excision Versus Ablation in Renal Cancer: Optimising Outcome and Minimising Risk. Eur Urol 2016;69:683–4. European Urology, 2016, 69, 684-685.	0.9	0
285	Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1037-1045.	0.4	21
286	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 533.e1-533.e10.	0.8	17
287	Association between lifetime alcohol consumption and prostate cancer risk: A case-control study in Montreal, Canada. Cancer Epidemiology, 2016, 45, 11-17.	0.8	25
288	Prognostic significance of markers of systemic inflammatory response in patients with non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 483.e17-483.e24.	0.8	54

#	Article	IF	Citations
289	Author Reply. Urology, 2016, 89, 68.	0.5	O
290	Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with Prostate Cancer Treated with Radical Prostatectomy. Journal of Urology, 2016, 196, 82-88.	0.2	17
291	Limitations of Elastography Based Prostate Biopsy. Journal of Urology, 2016, 195, 1731-1736.	0.2	20
292	Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses. Clinical Genitourinary Cancer, 2016, 14, e177-e182.	0.9	7
293	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World Journal of Urology, 2016, 34, 1411-1419.	1.2	10
294	Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study. European Urology, 2016, 70, 429-435.	0.9	16
295	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology, 2016, 34, 1155-1161.	1.2	4
296	Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 119.e11-119.e18.	0.8	14
297	Comparison of Postoperative Complications and Mortality Between Laparoscopic and Percutaneous Local Tumor Ablation for T1a Renal Cell Carcinoma: A Population-based Study. Urology, 2016, 89, 63-68.	0.5	15
298	Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e1-57.e7.	0.8	21
299	Prediction of Complications Following Partial Nephrectomy: Implications for Ablative Techniques Candidates. European Urology, 2016, 69, 676-682.	0.9	52
300	Heterogeneity in D׳Amico classification–based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 329.e13-329.e19.	0.8	37
301	Development and external validation of a prognostic tool for prediction of cancer-specific mortality after complete loco-regional pathological staging for squamous cell carcinoma of the penis. BJU International, 2015, 116, 734-743.	1.3	35
302	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. European Urology, 2015, 68, 949-956.	0.9	50
303	Waist circumference, waist-hip ratio, body mass index, and prostate cancer risk: Results from the North-American case-control study Prostate Cancer & Environment Study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 494.e1-494.e7.	0.8	40
304	The role of adjuvant chemotherapy for lymph nodeâ€positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. BJU International, 2015, 116, 72-78.	1.3	29
305	Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. European Urology, 2015, 68, 325-334.	0.9	239
306	The Role of Everolimus in Renal Cell Carcinoma. Journal of Kidney Cancer and VHL, 2015, 2, 187-194.	0.2	7

#	Article	IF	Citations
307	Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. Urology, 2014, 83, 863-868.	0.5	82
308	Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 49.e7-49.e14.	0.8	38
309	Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma. European Urology, 2014, 65, 1014-1015.	0.9	5
310	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 433-440.	0.8	31
311	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. European Urology, 2014, 65, 650-658.	0.9	134
312	Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 230-242.	0.8	33
313	Urine markers for detection and surveillance of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 222-229.	0.8	91
314	A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2014, 90, 49-57.	2.0	3
315	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. European Urology, 2014, 66, 666-672.	0.9	97
316	A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 46.e1-46.e7.	0.8	25
317	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2014, 65, 210-217.	0.9	201
318	Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. Journal of Urology, 2013, 189, 1214-1221.	0.2	291
319	Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. European Urology, 2013, 63, 1082-1090.	0.9	98
320	Prediction of Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development of an Optimized Postoperative Nomogram Using Decision Curve Analysis. Journal of Urology, 2013, 189, 1662-1669.	0.2	152
321	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroâ€ureterectomy. BJU International, 2013, 112, 453-461.	1.3	128
322	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. European Urology, 2012, 62, 677-684.	0.9	93
323	Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma. Journal of Urology, 2012, 187, 845-851.	0.2	57
324	The Impact of Tumor Multifocality on Outcomes in Patients Treated With Radical Nephroureterectomy. European Urology, 2012, 61, 245-253.	0.9	168

#	Article	IF	Citations
325	Predicting Clinical Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2012, 61, 818-825.	0.9	188
326	Pathological results and rates of treatment failure in highâ€risk prostate cancer patients after radical prostatectomy. BJU International, 2011, 107, 765-770.	1.3	120
327	Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. World Journal of Urology, 2011, 29, 473-480.	1.2	62
328	Advanced patient age is associated with inferior cancerâ€specific survival after radical nephroureterectomy. BJU International, 2010, 105, 1672-1677.	1.3	115
329	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. European Urology, 2010, 57, 575-581.	0.9	154
330	Prognostic Role of Lymphovascular Invasion in Patients with Urothelial Carcinoma of the Upper Urinary Tract: An International Validation Study. European Urology, 2010, 57, 1064-1071.	0.9	169
331	A delay in radical nephroureterectomy can lead to upstaging. BJU International, 2010, 105, 812-817.	1.3	90
332	Association of Tumor Necrosis With Pathological Features and Clinical Outcome in 754 Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An International Validation Study. Journal of Urology, 2010, 184, 1895-1900.	0.2	57
333	Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. Journal of Urology, 2010, 183, 68-75.	0.2	146
334	A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma. Urology, 2010, 75, 118-124.	0.5	144
335	The Extent of Lymphadenectomy Seems to Be Associated with Better Survival in Patients with Nonmetastatic Upper-Tract Urothelial Carcinoma: How Many Lymph Nodes Should Be Removed?. European Urology, 2009, 56, 512-519.	0.9	143
336	Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multiâ€institutional analysis of 1363 patients. BJU International, 2009, 103, 307-311.	1.3	160
337	Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: A population-based study of 2299 patients. European Journal of Cancer, 2009, 45, 3291-3297.	1.3	151
338	Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration. Journal of Urology, 2009, 182, 900-906.	0.2	200
339	External Validation of the Updated Partin Tables in a Cohort of North American Men. Journal of Urology, 2008, 180, 898-903.	0.2	36
340	Renal Cell Carcinoma with Nodal Metastases in the Absence of Distant Metastatic Disease: Prognostic Indicators of Disease-Specific Survival. European Urology, 2007, 51, 1616-1624.	0.9	93
341	Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU International, 2006, 97, 997-1001.	1.3	144
342	Prostate cancer nomograms are superior to neural networks. Canadian Journal of Urology, 2006, 13 Suppl 2, 18-25.	0.0	2

#	Article	IF	CITATIONS
343	DEVELOPMENT AND VALIDATION OF A NOMOGRAM PREDICTING THE OUTCOME OF PROSTATE BIOPSY BASED ON PATIENT AGE, DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE SPECIFIC ANTIGEN. Journal of Urology, 2005, 173, 1930-1934.	0.2	157
344	Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. Urology, 2005, 65, 131-135.	0.5	26